세계의 재조합 단백질 치료제 CDMO 시장 : 종류별, 적응증·공급원별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

REPORT HIGHLIGHT

Recombinant protein therapeutics CDMO Market size was valued at USD 20,920.32 Million in 2024, expanding to a CAGR of 13.98% from 2025 to 2032.

Recombinant protein therapeutics CDMO is specialized in recombinant protein therapeutics that provides services to biotech and pharmaceutical companies for the development, production, and scaling of protein-based drugs. These companies help in the end-to-end process, including cell line development, upstream and downstream processing, analytical testing, regulatory compliance, and large-scale manufacturing.

Recombinant protein therapeutics CDMO Market- Market Dynamics

Increasing demand for biologics and development in bioprocessing technologies are expected to propel market demand

The recombinant protein therapeutics CDMO market growth is driven by increasing demand for biologics, combined with the complexity of their production, has driven pharmaceutical and biotech companies to rely on specialized CDMOs. Biosimilars, which are cost-effective versions of original biologics, are gaining market acceptance, further driving the demand for CDMO services in recombinant protein production, boosting market growth. Single-use bioreactors, continuous manufacturing, and high-yield expression systems (such as CHO and HEK293 cells) have enhanced the efficiency of protein production. Innovations in upstream and downstream processing have improved protein yields, reducing overall production costs and timelines.

The rise of personalized medicine and precision therapeutics has increased demand for customized recombinant proteins. Recombinant protein-based cell and gene therapies are expanding the role of CDMOs in advanced biologics. Further, emerging applications in oncology, rare diseases, and regenerative medicine are fueling market growth. Asia-Pacific, particularly China, India, and South Korea, is becoming a hub for biopharmaceutical manufacturing due to lower costs and supportive government policies. Thus, many CDMOs are setting up facilities in these regions to cater to the growing demand for affordable biologics.

Recombinant protein therapeutics CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 13.98% over the forecast period (2025-2032)

Based on Type segmentation, the interferons segment was predicted to show maximum market share in the year 2024, due to high prevalence of infectious diseases.

Based on Indication segmentation, the others segment was the leading Indication segment in 2024, due to the high demand for protein therapeutics due to high prevalence disorders.

Based on Source segmentation, the mammalian systems segment was the leading Source segment in 2024, due to their high applications in human glycoproteins.

On the basis of region, Norh America was the leading revenue generator in 2024, owing to supportive government policies & development in transportation sector.

Recombinant protein therapeutics CDMO Market- Segmentation Analysis:

The Global Recombinant protein therapeutics CDMO Market is segmented on the basis of Type, Indication, Source, and Region.

The market is divided into five categories based on Type: growth hormones, interferons, vaccines, immunostimulant agents, and others. The interferons segment dominates the market. The increasing prevalence of infectious disorders is mainly spurring segment growth.

The market is divided into six categories based on Indication: oncology, infectious diseases, immunological disorders, metabolic disorders, hematological disorders, and others. The others segment is expected to hold the largest share. The metabolic disorders segment is expected to grow at the fastest rate over the forecast period.

The market is divided into three categories based on Source: mammalian system, microbial systems, and others. The mammalian systems segment holds the largest share of the source segment. The increasing applications biological drugs, genetical engineering are anticipated to bolster market growth.

Recombinant protein therapeutics CDMO Market- Geographical Insights

Across the world, the Recombinant protein therapeutics CDMO market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a prominent position in the recombinant protein therapeutics CDMO market. The United States has established itself as a global leader in the production of recombinant protein drugs. The country's strong research and development infrastructure and well-developed biopharmaceutical manufacturing capabilities contribute to market growth. The Asia-Pacific region is poised for significant growth in the recombinant protein therapeutics CDMO market. Factors contributing to this include a rising prevalence of chronic diseases, increased healthcare expenditures, and growing investments in biotechnology are offering growth opportunities. The Middle East and Africa are experiencing moderate growth in the recombinant protein therapeutics CDMO market.

Recombinant protein therapeutics CDMO Market- Competitive Landscape:

The recombinant protein therapeutics CDMO market is characterized by intense competition, with several key players striving to enhance their service offerings and expand their market presence. market participants offer a comprehensive range of services for the development and manufacture of biopharmaceuticals, including recombinant proteins. Some of the companies specialize in the development and manufacturing of therapeutic proteins, providing services from cell line development to commercial production.

Recent Developments:

In 2024, Novo Holdings announced a USD 16.5 billion acquisition of Catalent, planning to expand production capabilities for its successful weight-loss drugs.

In June 2023, Richter-Helm BioLogics announced the plan for the development of a production site in Bovenau, Europe.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET KEY PLAYERS

• Richter-Helm BioLogics
• Lonza
• Catalent, Inc
• FUJIFILM Diosynth Biotechnologies
• WuXi Biologics
• Curia Global, Inc.
• Batavia Biosciences B.V.
• AGC Biologics
• Boehringer Ingelheim BioXcellence
• Repligen Corporation
• Therapure BioPharma Inc.
• Cytovance Biologics
• KBI Biopharma
• Abzena
• Patheon
• Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

• Growth hormones
• Interferons
• Vaccines
• Immunostimulant agents
• Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

• Oncology
• Infectious Diseases
• Immunological disorders
• Metabolic disorders
• Hematological disorders
• Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY SOURCE- MARKET ANALYSIS, 2019-2032

• Mammalian system
• Microbial systems
• Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Recombinant Protein Therapeutics CDMO Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Recombinant Protein Therapeutics CDMO Market Snippet by Type
  • 2.1.2. Recombinant Protein Therapeutics CDMO Market Snippet by Indication
  • 2.1.3. Recombinant Protein Therapeutics CDMO Market Snippet by Source
  • 2.1.4. Recombinant Protein Therapeutics CDMO Market Snippet by Country
  • 2.1.5. Recombinant Protein Therapeutics CDMO Market Snippet by Region
• 2.2. Competitive Insights

3. Recombinant Protein Therapeutics CDMO Key Market Trends

• 3.1. Recombinant Protein Therapeutics CDMO Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Recombinant Protein Therapeutics CDMO Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Recombinant Protein Therapeutics CDMO Market Opportunities
• 3.4. Recombinant Protein Therapeutics CDMO Market Future Trends

4. Recombinant Protein Therapeutics CDMO Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Recombinant Protein Therapeutics CDMO Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Recombinant Protein Therapeutics CDMO Market Landscape

• 6.1. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Recombinant Protein Therapeutics CDMO Market - By Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
  • 7.1.2. Growth hormones
  • 7.1.3. Interferons
  • 7.1.4. Vaccines
  • 7.1.5. Immunostimulant agents
  • 7.1.6. Others

8. Recombinant Protein Therapeutics CDMO Market - By Indication

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
  • 8.1.2. Oncology
  • 8.1.3. Infectious Diseases
  • 8.1.4. Immunological disorders
  • 8.1.5. Metabolic disorders
  • 8.1.6. Hematological disorders
  • 8.1.7. Others

9. Recombinant Protein Therapeutics CDMO Market - By Source

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Source, 2024 & 2032 (%)
  • 9.1.2. Mammalian system
  • 9.1.3. Microbial systems
  • 9.1.4. Others

10. Recombinant Protein Therapeutics CDMO Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.8. UK
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8.5. UK Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.9. France
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9.5. France Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.10. Italy
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10.5. Italy Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.11. Spain
    • 10.3.11.1. Overview
    • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11.5. Spain Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.12. The Netherlands
    • 10.3.12.1. Overview
    • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12.5. The Netherlands Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Overview
    • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13.5. Sweden Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.14. Russia
    • 10.3.14.1. Overview
    • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14.5. Russia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.15. Poland
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Poland Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3.16. Rest of Europe
    • 10.3.16.1. Overview
    • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Asia Pacific
  • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4.6. APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.7. China
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7.5. China Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.8. India
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8.5. India Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.12. Indonesia
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Indonesia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.13. Thailand
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Thailand Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
• 10.5. Latin America (LATAM)
  • 10.5.1. Overview
  • 10.5.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Latin America
  • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5.6. LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa (MEA)
  • 10.6.1. Overview
  • 10.6.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Middle East and Africa
  • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6.6. MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.8. UAE
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8.5. UAE Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Recombinant Protein Therapeutics CDMO Industry

• 11.1. Competitive Dashboard
  • 11.1.1. Competitive Benchmarking
  • 11.1.2. Competitive Positioning
• 11.2. Company Profiles
  • 11.2.1. Richter-Helm BioLogics
  • 11.2.2. Lonza
  • 11.2.3. Catalent, Inc
  • 11.2.4. FUJIFILM Diosynth Biotechnologies
  • 11.2.5. WuXi Biologics
  • 11.2.6. Curia Global, Inc.
  • 11.2.7. Batavia Biosciences B.V.
  • 11.2.8. AGC Biologics
  • 11.2.9. Boehringer Ingelheim BioXcellence
  • 11.2.10. Repligen Corporation
  • 11.2.11. Therapure BioPharma Inc.
  • 11.2.12. Cytovance Biologics
  • 11.2.13. KBI Biopharma
  • 11.2.14. Abzena
  • 11.2.15. Patheon
  • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us